Eli Lilly and Company announced today that mirikizumab (an investigational interleukin-23p19 antagonist) met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of…
FDA approves BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic NSCLC. Pfizer announced that FDA has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as…
This new initiative marks a significant step forward in the Group’s philanthropic commitment, giving eligible employees the opportunity to make a smooth transition to retirement by participating in a 100% immersive experience in a non-profit organization. Eligible employees can take…
AbbVie today announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ® (upadacitinib) among adults and adolescents 12 years and older…
Luis Diaz Jr., MD, Head of the Division of Solid Tumor Oncology, and incumbent of the Grayer Family Chair, and Kojo S.J. Elenitoba-Johnson, MD, Chair of the Department of Pathology and Laboratory Medicine, Member in the Human Oncology Pathogenesis Program…
Amgen today announced that it has completed its acquisition of Horizon plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion. “Today marks an exciting milestone as we welcome Horizon employees to Amgen and…
Merck Healthcare, a leading science and technology company, today announced a new collaboration with the United Nations-guided Global Initiative on Ageing (GIA) to provide a training course on critical skills for family carers. The course, consisting of 5 modules, provides…
Cleveland Clinic has infused a new gene therapy to deliver a working gene to address the leading cause of hypertrophic cardiomyopathy (HCM) in the first patient in the world as part of a clinical trial. Myosin binding protein C3 (MYBPC3)…
The Icahn School of Medicine at Mount Sinai announced today that it has signed a memorandum of understanding with the Chiba Institute of Technology (CIT) to collaborate on using artificial intelligence (AI) for cardiovascular disease research. The goal is to…
A breakthrough technique developed by University of Oxford researchers could one day provide tailored repairs for those who suffer brain injuries. The researchers demonstrated for the first time that neural cells can be 3D printed to mimic the architecture of…